78 related articles for article (PubMed ID: 3515665)
1. Modified methotrexate regimen for prevention of graft-versus-host disease.
Vowels M; Lam-Po-Tang R; Mameghan H; Ford D; Hughes DO
Transplant Proc; 1986 Apr; 18(2):276-7. PubMed ID: 3515665
[No Abstract] [Full Text] [Related]
2. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
[No Abstract] [Full Text] [Related]
3. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
4. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate].
Shinohara Y; Kai S; Misawa M; Fujimori Y; Okamoto T; Kohsaki M; Kanamaru A; Ifuku H; Ohe Y; Hara H
Rinsho Ketsueki; 1986 Jan; 27(1):30-5. PubMed ID: 3520045
[No Abstract] [Full Text] [Related]
5. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
6. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
[No Abstract] [Full Text] [Related]
7. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
Hägglund H; Boström L; Ringdén O; Nilsson B; Remberger M
Transplant Proc; 1994 Jun; 26(3):1821-2. PubMed ID: 8030154
[No Abstract] [Full Text] [Related]
9. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation for acute leukemia in children. A short review.
Masotti A; Baccarani M
Haematologica; 1985; 70(6):536-44. PubMed ID: 3938434
[No Abstract] [Full Text] [Related]
11. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
12. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect.
Henslee PJ; Thompson JS; Romond EH; Doukas MA; Metcalfe M; Marshall ME; MacDonald JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):2701-6. PubMed ID: 3547948
[No Abstract] [Full Text] [Related]
13. Prevention of graft versus host disease following allogeneic bone marrow transplantation.
Powles RL; Goss GD; Millar J; Maitland J; Borthwick-Clark C; Al-Jundi A
Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738
[No Abstract] [Full Text] [Related]
14. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
Przepiorka D; Khouri I; Ippoliti C; Ueno NT; Mehra R; Körbling M; Giralt S; Gajewski J; Fischer H; Donato M; Cleary K; Claxton D; Chan KW; Braunschweig I; van Besien K; Andersson BS; Anderlini P; Champlin R
Bone Marrow Transplant; 1999 Oct; 24(7):763-8. PubMed ID: 10516680
[TBL] [Abstract][Full Text] [Related]
15. Prevention of graft-versus-host disease on an individual basis.
Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
[No Abstract] [Full Text] [Related]
16. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
17. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients.
Wingard JR; Nash RA; Ratanatharathorn V; Fay JW; Klein JL; Przepiorka D; Maher RM; Devine SM; Boswell G; Bekersky I; Fitzsimmons W
Bone Marrow Transplant; 1997 Jul; 20(1):49-51. PubMed ID: 9232256
[TBL] [Abstract][Full Text] [Related]
18. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
Perreault C; Gyger M; Boileau J; Bonny Y; Cousineau S; Lacombe M; Lavallee R; Tawil E; D'Angelo G
Can Med Assoc J; 1983 Nov; 129(9):969-74. PubMed ID: 6367917
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
